Hemarina SA (Hemarina) researches and develops marine oxygen carriers for therapeutic and industrial uses. The company develops hemoglobin-based oxygen carriers (HBOCs) for organ preservation. It provides an additive for organ preservation solution, oxygenating dressing for hypoxic and chronic wounds, oxygen carriers, and a cell growth activator for cell culture and recombinant protein production for research and development laboratories. The company also offers lead product, Hemarina M-101, which is under development that uses molecular-weight extracellular hemoglobin. It operates in the US and Noirmoutier Island. Hemarina is headquartered in Saint-Malo, France.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Hemarina SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Hemarina SA Company Overview
- Hemarina SA Company Snapshot
- Hemarina SA Pipeline Products and Ongoing Clinical Trials Overview
- Hemarina SA - Pipeline Analysis Overview
- Hemarina SA - Key Facts
- Hemarina SA - Major Products and Services
- Hemarina SA Pipeline Products by Development Stage
- Hemarina SA Ongoing Clinical Trials by Trial Status
- Hemarina SA Pipeline Products Overview
- Hemhealing
- Hemhealing Product Overview
- Hemo2life
- Hemo2life Product Overview
- Hemo2life Clinical Trial
- Hemoxycarrier
- Hemoxycarrier Product Overview
- Hemarina SA - Key Competitors
- Hemarina SA - Key Employees
- Hemarina SA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Hemarina SA, Recent Developments
- Nov 29, 2018: Hemarina and Delpharm team up to manufacture HEMO2life
- Jun 06, 2018: Brest University Hospital and HEMARINA Present Positive New Advances from the Initial Clinical Trial of HEMO2life at the American Transplant Congress in Seattle
- May 24, 2018: Hemarina announces positive preclinical proof of concept results on lung preservation before transplantation
- Apr 12, 2018: Hemarina And The University Health Network in Toronto Announce HEMO2life Novel Oxygen Carrier Positive Preclinical Proof Of Concept Results On Lung Preservation Before Transplantation
- Nov 14, 2017: Brest University Hospital and HEMARINA announce positive Top-line results from first clinical trial of HEMO2life in kidney preservation before human transplantation.
- Jul 26, 2016: Kidney transplant: OxyOp multicenter clinical trial evaluating the use of the oxygen carrier HEMO2life will continue in accordance with the protocol established
- Feb 09, 2016: Business France Announces Creative Next U.S. Contest Winner
- Feb 11, 2014: HEMARINA, ORPHY, the UBO laboratory, and the University Hospital of Brest launch HEMOXYCHOC, the preclinic project designed to assess the efficacy & safety of HEMOXYCarrier in the management of uncontrolled hemorrhagic shock
- Sep 26, 2013: HEMARINA & LFB Biomanufacturing announced the signature of an agreement for the manufacturing of HEMO2life
- Apr 30, 2013: HEMARINA expands its operations to Boston U.S.A. Hemarina will be the company affiliate for the America
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Hemarina SA Pipeline Products and Ongoing Clinical Trials Overview
- Hemarina SA Pipeline Products by Equipment Type
- Hemarina SA Pipeline Products by Indication
- Hemarina SA Ongoing Clinical Trials by Trial Status
- Hemarina SA, Key Facts
- Hemarina SA, Major Products and Services
- Hemarina SA Number of Pipeline Products by Development Stage
- Hemarina SA Pipeline Products Summary by Development Stage
- Hemarina SA Ongoing Clinical Trials by Trial Status
- Hemarina SA Ongoing Clinical Trials Summary
- Hemhealing - Product Status
- Hemhealing - Product Description
- Hemo2life - Product Status
- Hemo2life - Product Description
- Hemo2life - Evaluation at 5 and 10 Years of Renal Transplant Patients Who Received a Graft Preserved in a Solution HEMO2life
- Hemo2life - Evaluation of a Marine Oxygen Carrier (HEMO2Life) for hypothermic Kidney Graft Preservation Before Transplantation (OXYOP): 4 Years Follow-up
- Hemo2life - Evaluation of a Marine Oxygen Carrier for Organ Preservation : A Multicenter Randomized Study Evaluating the Efficacy of HEMO2life Versus Standard of Care in Renal Transplantation
- Hemo2life - Phase I Clinical Study Evaluating the Efficacy of HEMO2Life in COVID-19 Patients
- Hemoxycarrier - Product Status
- Hemoxycarrier - Product Description
- Hemarina SA, Key Employees
- Hemarina SA, Subsidiaries
- Glossary
- Hemarina SA Pipeline Products by Equipment Type
- Hemarina SA Pipeline Products by Development Stage
- Hemarina SA Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ImaBiotech SAS
- Atlanpole Biotherapies
- Gemac SA
